NewAmsterdam Pharma Co N.V.

This late-stage biopharmaceutical company focuses on developing therapies for cardiometabolic disorders in patient groups with inadequate or poorly tolerated existing treatment options. Its primary candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor investigated as a once-daily monotherapy or in a fixed-dose combination with ezetimibe. These investigational therapies serve as adjuncts to statin regimens to lower low-density lipoprotein cholesterol in individuals at risk of cardiovascular disease, atherosclerotic cardiovascular disease, and heterozygous familial hypercholesterolemia.

The company operates without commercial retail locations or operational store facilities, as its pipeline remains under clinical evaluation. Clinical research programs encompass studies conducted across multiple international regions, including the United States, Europe, Japan, and China, with pivotal trials enrolling thousands of participants globally. Commercialization and licensing rights are established in European countries via a third-party partnership, while United States rights remain retained internally. The text does not state the company's headquarters location.

Summary of the business section of NewAmsterdam Pharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 100 employees, consisting of clinical, research and development, business development, regulatory, finance and operational personnel.”